NASDAQ:TAOX Synaptogenix (TAOX) Stock Price, News & Analysis $3.44 -0.05 (-1.43%) Closing price 08/6/2026 04:00 PM EasternExtended Trading$3.41 -0.03 (-0.87%) As of 08/6/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsSEC FilingsTrendsBuy This Stock About Synaptogenix Stock (NASDAQ:TAOX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Synaptogenix alerts:Sign Up Key Stats Today's Range$3.34▼$3.5850-Day Range$3.23▼$4.2152-Week Range$3.18▼$10.00Volume34,604 shsAverage Volume86,093 shsMarket Capitalization$25.70 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York. Read More Synaptogenix Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks6th Percentile Overall ScoreTAOX MarketRank™: Synaptogenix scored higher than 6% of companies evaluated by MarketBeat, and ranked 873rd out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingSynaptogenix has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageSynaptogenix has only been the subject of 1 research reports in the past 90 days.Read more about Synaptogenix's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Synaptogenix is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Synaptogenix is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSynaptogenix has a P/B Ratio of 1.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.93% of the float of Synaptogenix has been sold short.Short Interest Ratio / Days to CoverSynaptogenix has a short interest ratio ("days to cover") of 5.16.Change versus previous monthShort interest in Synaptogenix has recently decreased by 5.64%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSynaptogenix does not currently pay a dividend.Dividend GrowthSynaptogenix does not have a long track record of dividend growth. News and Social MediaN/ANews SentimentN/A Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Synaptogenix insiders have not sold or bought any company stock.Percentage Held by Insiders2.70% of the stock of Synaptogenix is held by insiders.Percentage Held by Institutions10.34% of the stock of Synaptogenix is held by institutions.Read more about Synaptogenix's insider trading history. Receive TAOX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Synaptogenix and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TAOX Stock News HeadlinesTAO Synergies Appoints Bittensor Investor and Author Mark Jeffrey as AdvisorJuly 8, 2026 | prnewswire.comTAO Synergies Set to Join the Russell Microcap® Index as a Leading Public Gateway to Decentralized AIJune 16, 2026 | prnewswire.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow. | Base Camp Trading (Ad)TAO Synergies and Yuma Asset Management to Host Livestream on X: Bittensor (TAO) and DeAI InnovationNovember 18, 2025 | prnewswire.comTradr Set to Debut ETFs Targeting Bloom Energy, Celestica, Nano Nuclear and SynopsysNovember 11, 2025 | prnewswire.comTAO Synergies Announces Initial $750,000 Investment in Yuma Asset Management's Subnet FundsNovember 4, 2025 | prnewswire.comTAO Synergies Raises Bittensor (TAO) Holdings to over 54,000 Tokens, Largest Publicly Traded Holder of Top Decentralized AI CryptocurrencyOctober 20, 2025 | prnewswire.comTAO Synergies Announces $11 Million Private PlacementOctober 13, 2025 | prnewswire.comSee More Headlines TAOX Stock Analysis - Frequently Asked Questions How have TAOX shares performed this year? Synaptogenix's stock was trading at $3.68 at the start of the year. Since then, TAOX stock has decreased by 6.5% and is now trading at $3.44. How were Synaptogenix's earnings last quarter? Synaptogenix, Inc. (NASDAQ:TAOX) issued its quarterly earnings results on Wednesday, May, 13th. The company reported $0.43 earnings per share (EPS) for the quarter. The firm earned $5.96 million during the quarter. How do I buy shares of Synaptogenix? Shares of TAOX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/13/2026Today8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 TAOX's financial health is in the Yellow zone, according to TradeSmith. TAOX has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:TAOX Previous SymbolNASDAQ:SNPX CIK1571934 WebN/A Phone(973) 242-0005FaxN/AEmployees4Year FoundedN/AProfitability EPS (Trailing Twelve Months)($13.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$28.74 million Net MarginsN/A Pretax Margin-3,635.47% Return on Equity-163.40% Return on Assets-133.47% Debt Debt-to-Equity RatioN/A Current Ratio27.39 Quick Ratio27.39 Sales & Book Value Annual Sales$687.84 thousand Price / Sales37.37 Cash FlowN/A Price / Cash FlowN/A Book Value$2.83 per share Price / Book1.22Miscellaneous Outstanding Shares7,472,000Free Float7,270,000Market Cap$25.70 million OptionableN/A Beta1.45 The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:TAOX) was last updated on 8/7/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synaptogenix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Synaptogenix With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
